Global Genomic Biomarker Market Size By Type, By Disease Indication Geographic Scope And Forecast

Report ID: 290009|No. of Pages: 202

product image

Global Genomic Biomarker Market Size By Type, By Disease Indication Geographic Scope And Forecast

Report ID: 290009|Published Date: May 2024|No. of Pages: 202|Base Year for Estimate: 2024|Format:   Report available in PDF formatReport available in Excel Format

Genomic Biomarker Market Size And Forecast

Genomic Biomarker Market size was valued at USD 932.81 Million in 2024 and is projected to reach USD 1532.24 Million by 2031, growing at a CAGR of 6.40% during the forecast period 2024-2031.

Genomic Biomarker Market is estimated to grow at a CAGR of 6.40% & reach US$ 1532.24 Bn by the end of 2031

Global Genomic Biomarker Market Drivers

The market drivers for the Genomic Biomarker Market can be influenced by various factors. These may include:

  • Progress in Genomic Technologies: The range and precision of biomarker detection and analysis have been increased by the ongoing developments in genotyping, genomic sequencing, and other genomic technologies.
  • Growing frequency of Chronic Diseases: The need for genomic biomarkers for early detection, diagnosis, prognosis, and personalised treatment has been stoked by the rising frequency of chronic diseases, including cancer, cardiovascular disease, and neurological disorders.
  • Growing Need for Personalised Medicine: Genomic biomarkers are essential to personalised medicine because they allow customised treatment regimens based on a patient’s genetic composition, which improves treatment outcomes and lowers side effects.
  • Growing Emphasis on Precision Medicine Initiatives: Government funding and initiatives, especially in industrialised nations, have sparked research and development efforts in genomic biomarkers with the goal of enhancing precision medicine.
  • Growing Use in Clinical Trials and Drug Development: Genomic biomarkers are being used more frequently in clinical trials and drug development to find patient subgroups who are more likely to respond to particular treatments. This increases the effectiveness of medication research and lowers expenses.
  • Technological Advancements in Biomarker Discovery: New genomic biomarkers with higher sensitivity and specificity are being found thanks to ongoing technological advancements including next-generation sequencing (NGS), CRISPR-Cas9 gene editing, and single-cell analysis methods.
  • Growing Adoption of Companion Diagnostics: As companion diagnostics play a bigger role in helping patients make treatment decisions, the need for genomic biomarkers is rising. Companion diagnostics are used to identify patients who are most likely to benefit from a specific therapeutic product.
  • Growing Research Partnerships and Collaborations: The conversion of genomic research discoveries into clinically useful biomarkers is happening faster because to partnerships and collaborations between pharmaceutical companies, academic institutions, and diagnostic businesses for biomarker development and validation.
  • Growing Acceptance and Awareness of genetic Testing: The market for genetic biomarkers is growing as more people, including medical professionals and patients, become aware of the advantages of genomic testing for illness prevention, diagnosis, and treatment.
  • genome Sequencing Cost Reduction: As a result of declining genome sequencing technology costs and advancements in data analysis and interpretation, the market for genomic biomarker testing is expanding and becoming more widely available and affordable.

Global Genomic Biomarker Market Restraints

Several factors can act as restraints or challenges for the Genomic Biomarker Market. These may include:

  • Regulatory Obstacles: Tight regulations requiring genetic biomarkers to be approved may provide barriers to their commercialization. It can be costly and time-consuming to ensure adherence to regulatory norms, such as FDA clearances in the US and comparable laws in other nations.
  • Legal and Ethical Issues: The use of genomic biomarkers frequently necessitates the gathering and examination of private genetic data. This presents questions about consent, privacy, and the misuse of genetic data, which are ethical and legal issues. It can be difficult to address these issues and guarantee appropriate data protection procedures.
  • High Cost of Development and Implementation: Research, development, and validation studies must be heavily invested in in order to develop genetic biomarkers. Furthermore, setting up the infrastructure for genomic testing in medical facilities can be expensive. Access to genetic biomarker testing may be restricted by high costs, particularly in environments with limited resources.
  • Complexity of Data Interpretation: The interpretation of genomic data can be challenging, requiring advanced bioinformatics tools and specialised knowledge. Clinical decision-making depends on the precise and trustworthy interpretation of genomic biomarker data, which can be difficult, especially for medical professionals without specialised training in genomics.
  • Limited Clinical Utility and Validation: In practical contexts, not all genetic biomarkers have demonstrated clinical utility or validation. The lack of sufficient data to demonstrate the clinical validity and usefulness of some biomarkers may prevent payers and healthcare providers from using them.
  • Interoperability and Standardisation: Data sharing and collaboration between researchers and healthcare organisations might be hampered by a lack of interoperability and standardisation in genomic data formats and analytic processes. To optimise the use of genetic biomarkers, consistent standards for genomic data analysis and interchange must be established.
  • Education of Patients and Physicians: It’s possible that neither patients nor physicians fully comprehend the significance of genetic biomarkers in healthcare decision-making. To promote acceptance and implementation of genetic biomarkers, it is imperative to enhance education and understanding regarding genomic medicine.

Global Genomic Biomarker Market Segmentation Analysis

The Global Genomic Biomarker Market is Segmented on the basis of Type, Disease Indication And Geography.

Genomic Biomarker Market Segmentation Analysis

Genomic Biomarker Market, By Type

  • Predictive Biomarkers: These biomarkers are used to identify individuals who are at risk of developing a particular disease.
  • Prognostic Biomarkers: These biomarkers are used to predict the course of a disease after it has been diagnosed.

Genomic Biomarker Market, By Disease Indication

  • Oncology (Cancer): This segment is the largest and is expected to grow the fastest, due to the increasing use of genomic biomarkers in cancer diagnosis and treatment. ![Cancer Cells]
  • Cardiovascular Diseases: Biomarkers can help assess risk and predict heart disease
  • Neurological Diseases: This segment includes conditions like Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis.
  • Renal Disorders: Biomarkers aid in diagnosis and prognosis of kidney diseases.
  • Others: This segment includes infectious diseases, autoimmune diseases, and metabolic disorders.

Genomic Biomarker Market, By Geography

  • North America: Market conditions and demand in the United States, Canada, and Mexico.
  • Europe: Analysis of the Genomic Biomarker Market in European countries.
  • Asia-Pacific: Focusing on countries like China, India, Japan, South Korea, and others.
  • Middle East and Africa: Examining market dynamics in the Middle East and African regions.
  • Latin America: Covering market trends and developments in countries across Latin America.

Key Players

The major players in the Genomic Biomarker Market are:

  • Cancer Genetics Inc
  • Eurofins Scientific
  • Thermo Fisher Scientific Inc
  • Aepodia SA
  • Epigenomics AG
  • US Biomarkers Inc.
  • Roche Diagnostics
  • Myriad Genetics
  • Illumina Inc.
  • QIAGEN N.V.
  • PerkinElmer
  • Oxford Nanopore Technologies Ltd.
  • BGI Group
  • Macrogen Inc.
  • GENEWIZ
  • Novogene Corporation

Report Scope

REPORT ATTRIBUTESDETAILS
Study Period

2021-2031

Base Year

2024

Forecast Period

2024-2031

Historical Period

2020-2022

Unit

Value (USD Million)

Key Companies Profiled

Cancer Genetics Inc, Eurofins Scientific, Thermo Fisher Scientific Inc, Aepodia SA, Epigenomics AG, Roche Diagnostics, Myriad Genetics, Illumina Inc., QIAGEN N.V. , Oxford Nanopore Technologies Ltd.

Segments Covered
  • By Type
  • By Disease Indication
  • By Geography
Customization Scope

Free report customization (equivalent to up to 4 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

Top Trending Reports:

Global Cleviprex Market Size And Forecast 

Global Clear Borosilicate Glass Tube Market Size And Forecast

Research Methodology of Verified Market Research:

Research Methodology of VMR

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our Sales Team at Verified Market Research.

Reasons to Purchase this Report:

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support

Customization of the Report

• In case of any Queries or Customization Requirements please connect with our sales team, who will ensure that your requirements are met.

Frequently Asked Questions

Genomic Biomarker Market was valued at USD 932.81 Million in 2024 and is projected to reach USD 1532.24 Million by 2031, growing at a CAGR of 6.40% during the forecast period 2024-2031.

Growing Frequency Of Chronic Diseases, Progress In Genomic Technologies, Growing Need For Personalised Medicine and Growing Adoption Of Companion Diagnostics are the factors driving the growth of the Genomic Biomarker Market.

The major players are Cancer Genetics Inc, Eurofins Scientific, Thermo Fisher Scientific Inc, Aepodia SA, Epigenomics AG, Roche Diagnostics, Myriad Genetics, Illumina Inc., QIAGEN N.V. , Oxford Nanopore Technologies Ltd.

The Global Genomic Biomarker Market is Segmented on the basis of Type, Disease Indication And Geography.

The sample report for the Genomic Biomarker Market can be obtained on demand from the website. Also, the 24*7 chat support & direct call services are provided to procure the sample report.

1. Introduction
• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary
• Key Findings
• Market Overview
• Market Highlights

3. Market Overview
• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter’s Five Forces Analysis

4. Genomic Biomarker Market, By Type
• Predictive Biomarkers
• Prognostic Biomarkers

5. Genomic Biomarker Market, By Disease Indication
• Oncology (Cancer)
• Cardiovascular Diseases
• Neurological Diseases
• Renal Disorders

6. Regional Analysis
• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

7. Market Dynamics
• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

8. Competitive Landscape
• Key Players
• Market Share Analysis

9. Company Profiles
• Cancer Genetics Inc
• Eurofins Scientific
• Thermo Fisher Scientific Inc
• Aepodia SA
• Epigenomics AG
• US Biomarkers Inc.
• Roche Diagnostics
• Myriad Genetics
• Bio-Rad Laboratories

10. Market Outlook and Opportunities
• Emerging Technologies
• Future Market Trends
• Investment Opportunities

11. Appendix
• List of Abbreviations
• Sources and References

Report Research Methodology

Research methodology

Verified Market Research uses the latest researching tools to offer accurate data insights. Our experts deliver the best research reports that have revenue generating recommendations. Analysts carry out extensive research using both top-down and bottom up methods. This helps in exploring the market from different dimensions.

This additionally supports the market researchers in segmenting different segments of the market for analysing them individually.

We appoint data triangulation strategies to explore different areas of the market. This way, we ensure that all our clients get reliable insights associated with the market. Different elements of research methodology appointed by our experts include:

Exploratory data mining

Market is filled with data. All the data is collected in raw format that undergoes a strict filtering system to ensure that only the required data is left behind. The leftover data is properly validated and its authenticity (of source) is checked before using it further. We also collect and mix the data from our previous market research reports.

All the previous reports are stored in our large in-house data repository. Also, the experts gather reliable information from the paid databases.

expert data mining

For understanding the entire market landscape, we need to get details about the past and ongoing trends also. To achieve this, we collect data from different members of the market (distributors and suppliers) along with government websites.

Last piece of the ‘market research’ puzzle is done by going through the data collected from questionnaires, journals and surveys. VMR analysts also give emphasis to different industry dynamics such as market drivers, restraints and monetary trends. As a result, the final set of collected data is a combination of different forms of raw statistics. All of this data is carved into usable information by putting it through authentication procedures and by using best in-class cross-validation techniques.

Data Collection Matrix

PerspectivePrimary ResearchSecondary Research
Supplier side
  • Fabricators
  • Technology purveyors and wholesalers
  • Competitor company’s business reports and newsletters
  • Government publications and websites
  • Independent investigations
  • Economic and demographic specifics
Demand side
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customer

Econometrics and data visualization model

data visualiztion model

Our analysts offer market evaluations and forecasts using the industry-first simulation models. They utilize the BI-enabled dashboard to deliver real-time market statistics. With the help of embedded analytics, the clients can get details associated with brand analysis. They can also use the online reporting software to understand the different key performance indicators.

All the research models are customized to the prerequisites shared by the global clients.

The collected data includes market dynamics, technology landscape, application development and pricing trends. All of this is fed to the research model which then churns out the relevant data for market study.

Our market research experts offer both short-term (econometric models) and long-term analysis (technology market model) of the market in the same report. This way, the clients can achieve all their goals along with jumping on the emerging opportunities. Technological advancements, new product launches and money flow of the market is compared in different cases to showcase their impacts over the forecasted period.

Analysts use correlation, regression and time series analysis to deliver reliable business insights. Our experienced team of professionals diffuse the technology landscape, regulatory frameworks, economic outlook and business principles to share the details of external factors on the market under investigation.

Different demographics are analyzed individually to give appropriate details about the market. After this, all the region-wise data is joined together to serve the clients with glo-cal perspective. We ensure that all the data is accurate and all the actionable recommendations can be achieved in record time. We work with our clients in every step of the work, from exploring the market to implementing business plans. We largely focus on the following parameters for forecasting about the market under lens:

  • Market drivers and restraints, along with their current and expected impact
  • Raw material scenario and supply v/s price trends
  • Regulatory scenario and expected developments
  • Current capacity and expected capacity additions up to 2027

We assign different weights to the above parameters. This way, we are empowered to quantify their impact on the market’s momentum. Further, it helps us in delivering the evidence related to market growth rates.

Primary validation

The last step of the report making revolves around forecasting of the market. Exhaustive interviews of the industry experts and decision makers of the esteemed organizations are taken to validate the findings of our experts.

The assumptions that are made to obtain the statistics and data elements are cross-checked by interviewing managers over F2F discussions as well as over phone calls.

primary validation

Different members of the market’s value chain such as suppliers, distributors, vendors and end consumers are also approached to deliver an unbiased market picture. All the interviews are conducted across the globe. There is no language barrier due to our experienced and multi-lingual team of professionals. Interviews have the capability to offer critical insights about the market. Current business scenarios and future market expectations escalate the quality of our five-star rated market research reports. Our highly trained team use the primary research with Key Industry Participants (KIPs) for validating the market forecasts:

  • Established market players
  • Raw data suppliers
  • Network participants such as distributors
  • End consumers

The aims of doing primary research are:

  • Verifying the collected data in terms of accuracy and reliability.
  • To understand the ongoing market trends and to foresee the future market growth patterns.

Industry Analysis Matrix

Qualitative analysisQuantitative analysis
  • Global industry landscape and trends
  • Market momentum and key issues
  • Technology landscape
  • Market’s emerging opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2027
  • Market revenue estimates and forecasts up to 2027, by technology
  • Market revenue estimates and forecasts up to 2027, by application
  • Market revenue estimates and forecasts up to 2027, by type
  • Market revenue estimates and forecasts up to 2027, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

Genomic Biomarker Market

report-detail

Download Sample Report

View More Reports